Grail, Inc. (NASDAQ:GRAL - Get Free Report)'s stock price dropped 6.6% on Friday . The stock traded as low as $42.00 and last traded at $44.60. Approximately 558,219 shares changed hands during trading, a decline of 61% from the average daily volume of 1,429,129 shares. The stock had previously closed at $47.76.
Wall Street Analyst Weigh In
Several research firms have recently commented on GRAL. Wolfe Research started coverage on Grail in a report on Friday, November 15th. They issued a "peer perform" rating for the company. Morgan Stanley initiated coverage on shares of Grail in a research note on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 price target for the company.
Check Out Our Latest Research Report on Grail
Grail Trading Down 4.8 %
The business has a fifty day moving average of $27.15 and a 200 day moving average of $19.44.
Grail (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.86) EPS for the quarter, topping the consensus estimate of ($4.41) by $2.55. The business had revenue of $38.25 million for the quarter, compared to the consensus estimate of $35.33 million. On average, analysts forecast that Grail, Inc. will post -15.15 EPS for the current fiscal year.
Hedge Funds Weigh In On Grail
Several large investors have recently modified their holdings of GRAL. Crcm LP acquired a new position in Grail in the 4th quarter valued at about $65,061,000. Sessa Capital IM L.P. bought a new stake in shares of Grail during the fourth quarter worth approximately $53,550,000. Primecap Management Co. CA acquired a new position in shares of Grail in the fourth quarter valued at approximately $37,118,000. Baker BROS. Advisors LP acquired a new position in shares of Grail in the fourth quarter valued at approximately $29,098,000. Finally, Vanguard Group Inc. bought a new position in shares of Grail during the fourth quarter worth approximately $25,902,000.
About Grail
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Recommended Stories
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
